Drug Trial Radar · NCT03700320
Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
Last checked: Nov 20, 2026Latest source record: Jun 15, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
744
Actual
Start
Oct 8, 2018
Primary completion
May 21, 2020
Study completion May 21, 2020
Sponsor
- Lead sponsor
- AllerganAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Oct 9, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate safety and tolerability of treatment with atogepant for the prevention of episodic migraine over the course of one year.
Conditions
- Episodic Migraine
Interventions
Standard of Care (SOC) Migraine Preventive MedicationDrug
Standard of care medication selected based on investigator's judgement, recognized as safe and effective for the prevention of migraine.
AtogepantDrug
Atogepant tablets taken orally, once daily for 52 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With at Least 1 Treatment Emergent Adverse Event (TEAE)Time frame: From first dose up to the end of study (median treatment of 52 weeks) + 4 weeks follow-up
Locations
112 sites in 1 country. Site status is shown where the registry gives one.
Clinical Research Advantage, Inc./Simon Williamson Clinic, PC
Birmingham, Alabama
Achieve Clinical Research, LLC
Birmingham, Alabama
Synexus Clinical Research US, Inc./East Valley Family Physicians PLC
Chandler, Arizona
Synexus Clinical Research US, Inc./Desert Clinical Research, LLC
Mesa, Arizona
Synexus Clinical Research US, Inc./Central Phoenix Medical Clinic, LLC
Phoenix, Arizona
Anaheim Clinical Trials, LLC
Anaheim, California
Hope Clinical Research
Canoga Park, California
Pharmacology Research Institute
Encino, California
Sun Valley Research Center, Inc.
Imperial, California
Irvine Center for Clinical Research
Irvine, California
Grossmont Center for Clinical Research
La Mesa, California
Synergy San Diego
Lemon Grove, California
Collaborative Neuroscience Network, LLC.
Long Beach, California
Pharmacology Research Institute
Los Alamitos, California
Pacific Research Partners, LLC
Oakland, California
Excell Research, Inc.
Oceanside, California
Desert Valley Research
Redlands, California
Medical Center for Clinical Research
San Diego, California
California Research Foundation
San Diego, California
Artemis Institute for Clinical Research
San Marcos, California
California Medical Clinic for Headache
Santa Monica, California
Encompass Clinical Research
Spring Valley, California
Synexus Clinical Research US, Inc.
Vista, California
Diablo Clinical Research, Inc
Walnut Creek, California
Delta Waves, Inc.
Colorado Springs, Colorado
Advanced Neurosciences Research, LLC
Fort Collins, Colorado
MD Clinical
Hallandale, Florida
Infinity Clinical Research
Hollywood, Florida
Clinical Neuroscience Solutions
Jacksonville, Florida
Health Awareness, Inc.
Jupiter, Florida
Meridien Research
Maitland, Florida
Well Pharma Medical Research, Corp.
Miami, Florida
Sensible Healthcare LLC
Ocoee, Florida
Clinical Neuroscience Solutions, Inc
Orlando, Florida
Bioclinica Research
Orlando, Florida
Infinity Clinical Research LLC
Sunrise, Florida
Meridien Research
Tampa, Florida
Premiere Research Institute
West Palm Beach, Florida
Palm Beach Research Center
West Palm Beach, Florida
Synexus Clinical Research US, Inc.
Atlanta, Georgia
Showing 40 of 112 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.